Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Luc Friboulet

research director

Institut Gustave Roussy

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Collaborators (7)

Catline NOBRE

Institut Gustave Roussy

Cristina Teixido

Hospital Clínic de Barcelona

Benjamin Besse

Université Paris-Saclay

Arianna Marinello

Institut Gustave Roussy

Tilman Brummer

University Professor and lab head

University of Freiburg

Francesco Facchinetti

Institut Gustave Roussy

Sven Diederichs

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Luc Friboulet

Research Interests

Make your next move.

Explore related searches

Articles (20)

Collaborators (7)

Catline NOBRE

Cristina Teixido

Benjamin Besse

Arianna Marinello

Tilman Brummer

Francesco Facchinetti

Sven Diederichs

Make your next move.

Luc Friboulet

Research Interests

Make your next move.

Explore related searches

Articles (20)

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors

Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort

Characterization of TKI-induced drug-tolerant persister cells from patient-derived cell lines.

Single-cell transcriptomic analysis of treatment-persistent residual disease in BRAF-mutant lung adenocarcinoma.

Single-nuclei multiomic profiling reveals conserved adaptive states in EGFR- and ALK-mutant lung adenocarcinoma

BRAF Kinase Domain Duplication as a Potential On-Target Resistance Mechanism After Dabrafenib-Trametinib Therapy in a Patient With BRAF V600E -Mutated Lung Adenocarcinoma

Saturation mutational scanning uncovers druggability of all FGFR kinase point mutations

Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

CIRCULATING TUMOR DNA IN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: A PROOF-OF-CONCEPT STUDY

Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients

Istiratumab exhibits antiproliferative activity in Ewing sarcoma and rhabdomyosarcoma

New therapeutic approaches in NUT carcinoma: An unmet need

Paired liquid biopsies analysis reveals resistance mechanisms and prognostic factors in patients treated with KRASG12C inhibitors

Personalized Therapy in a Patient With<i> EGFR-</i> Mutated NSCLC Developing Sequential<i> CCDC6-RET</i> Fusion and<i> BRAF</i> V600E Mutation as Bypass Resistance Mechanisms

Recurrent resistance mutations to lirafugratinib delineate treatment sequences for FGFR2-driven tumors

Retrospective analysis of FGFR-TKI efficacy in patients treated at Gustave Roussy: Impact of FGFR alteration type, tumor type, and rechallenge therapy

Single-cell RNA sequencing reveals EMT-activated fibroblast subset as a key mechanism of resistance to immune checkpoint blockers in NSCLC

UNLOCK, a preclinical platform of PDX models resistant to innovative therapies

Collaborators (7)

Catline NOBRE

Cristina Teixido

Benjamin Besse

Arianna Marinello

Tilman Brummer

Francesco Facchinetti

Sven Diederichs

Make your next move.